When was Phenex Pharma founded?

Phenex Pharma was founded in 2002 and raised its 1st funding round 3 years after it was founded.

Where is Phenex Pharma located?

Phenex Pharma is headquartered in Ludwigshafen, Germany.

Who is the current CEO of Phenex Pharma?

Claus Kremoser of Phenex Pharma.

How many employees does Phenex Pharma have?

As of Dec 31, 2020, the latest employee count at Phenex Pharma is 21.

Is Phenex Pharma a funded company?

Phenex Pharma is a funded company, having raised a total of $24.5M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 11, 2005.

When was the latest funding round of Phenex Pharma?

Phenex Pharma's latest funding was a $***** Series C round on Sep 21, 2010, with participation from 6 investors.

Where does Phenex Pharma rank among its competitors?

Phenex Pharma ranks 158th amongst 394 active competitors, of which 147 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Generate Biomedicines, which secured an undisclosed amount in Dec, 2024.

Who are the top competitors of Phenex Pharma?

Phenex Pharma's top competitors include ADMA Biologics, BioNTech and Abcellera Biologics. Among them, Generate Biomedicines secured the most recent funding round in December, 2024.

Phenex Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Phenex Pharma is a public company based in Ludwigshafen (Germany), founded in 2002. It operates as a Developer of small molecules targeting nuclear receptors for the treatment of liver diseases & autoimmune diseases. Phenex Pharma has raised $24.5M in funding from Creathor Venture and LBBW Venture Capital. The company has 394 active competitors, including 147 funded and 108 that have exited. Its top competitors include companies like ADMA Biologics, BioNTech and Abcellera Biologics.

Company Details

Developer of small molecules targeting nuclear receptors for the treatment of liver diseases & autoimmune diseases. The drug candidates include PX-102 for the treatment of metabolic syndrome/non-alcoholic fatty liver disease/NASH; and Retinoid-Acid Receptor-related Orphan Receptor gamma inverse agonists for the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis.

Website: phenex-pharma.com
Social

Key Metrics

Founded Year

2002

Location

Ludwigshafen, Germany

Stage

Public

Total Funding

$24.5M in 3 rounds

Latest Funding Round

Series C, Sep 21, 2010, $*****

Investors

Creathor Venture & 6 more

Ranked

158^th among 394 active competitors

Employee Count

21 as on Dec 31, 2020

Similar Companies

ADMA Biologics & 463 more

Exit Details

Public

View Phenex Pharma's full profile

Phenex Pharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Phenex Pharmaceuticals Ag CIN: HRB734710 , Germany, Active	Oct 15, 2019	-	21 (As on Dec 31, 2020)

Phenex Pharma has raised a total funding of $24.5M over 3 rounds. Its first funding round was on Oct 11, 2005. Its latest funding round was a Series C round on Sep 21, 2010 for $*****. 6 investors participated in its latest round. Phenex Pharma has 7 institutional investors.

Here is the list of recent funding rounds of Phenex Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 21, 2010	6856136	Series C	9813745	2215524	2334639	5282439
Oct 02, 2008	8200136	Series B	2914606	4550663	4504917	Kfw & 2 more
Oct 11, 2005	3478518	Series A	8971588	9944175	5103733	Kfw & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Phenex Pharma's funding rounds and investors

Phenex Pharma's employee count trend

Phenex Pharma has 21 employees as of Dec 20. The total employee count is 32.0% lower than what it was in Dec 19. Here is Phenex Pharma's employee count trend over the years:

Uncover Phenex Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Phenex Pharma include ADMA Biologics, BioNTech and Abcellera Biologics. Here is the list of Top 10 competitors of Phenex Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	71/100
2nd	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Redmile Group, Fidelity Investments & 28 others	69/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	69/100
4th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, SR One & 20 others	68/100
5th	Apellis Pharmaceuticals 2008, Crestwood (United States), Public	Developer of therapeutics for the treatment of rare diseases	$213M	Sectoral, VenBio & 21 others	68/100
6th	PureTech Health 2001, Boston (United States), Public	Developer of immunotherapeutics for multiple diseases	$107M	Vitruvian Partners, Invesco Perpetual	67/100
7th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Boxer Capital, Deerfield & 5 others	67/100
8th	Vera Therapeutics 2016, San Francisco (United States), Public	Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases	$197M	Abingworth, Citadel & 13 others	66/100
9th	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	March Capital, Amgen & 14 others	66/100
10th	Astria 2008, Boston (United States), Acquired	Developer of therapeutics for rare diseases	$117M	MedImmune Ventures, Perceptive Advisors & 3 others	65/100
158th	Phenex Pharma 2002, Ludwigshafen (Germany), Public	Developer of small molecules targeting nuclear receptors for the treatment of liver diseases & autoimmune diseases	$24.5M	CD-Venture, Kfw & 5 others	40/100